259 related articles for article (PubMed ID: 9722511)
1. Cooperative interaction between alpha- and beta-chains of hepatocyte growth factor on c-Met receptor confers ligand-induced receptor tyrosine phosphorylation and multiple biological responses.
Matsumoto K; Kataoka H; Date K; Nakamura T
J Biol Chem; 1998 Sep; 273(36):22913-20. PubMed ID: 9722511
[TBL] [Abstract][Full Text] [Related]
2. HGF/NK4 is a specific antagonist for pleiotrophic actions of hepatocyte growth factor.
Date K; Matsumoto K; Shimura H; Tanaka M; Nakamura T
FEBS Lett; 1997 Dec; 420(1):1-6. PubMed ID: 9450538
[TBL] [Abstract][Full Text] [Related]
3. Nk4, a new HGF/SF variant, is an antagonist to the influence of HGF/SF on the motility and invasion of colon cancer cells.
Parr C; Hiscox S; Nakamura T; Matsumoto K; Jiang WG
Int J Cancer; 2000 Feb; 85(4):563-70. PubMed ID: 10699931
[TBL] [Abstract][Full Text] [Related]
4. HGF/NK4, a four-kringle antagonist of hepatocyte growth factor, is an angiogenesis inhibitor that suppresses tumor growth and metastasis in mice.
Kuba K; Matsumoto K; Date K; Shimura H; Tanaka M; Nakamura T
Cancer Res; 2000 Dec; 60(23):6737-43. PubMed ID: 11118060
[TBL] [Abstract][Full Text] [Related]
5. Kringle 1-4 of hepatocyte growth factor inhibits proliferation and migration of human microvascular endothelial cells.
Kuba K; Matsumoto K; Ohnishi K; Shiratsuchi T; Tanaka M; Nakamura T
Biochem Biophys Res Commun; 2000 Dec; 279(3):846-52. PubMed ID: 11162438
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of tumor growth and invasion by a four-kringle antagonist (HGF/NK4) for hepatocyte growth factor.
Date K; Matsumoto K; Kuba K; Shimura H; Tanaka M; Nakamura T
Oncogene; 1998 Dec; 17(23):3045-54. PubMed ID: 9881707
[TBL] [Abstract][Full Text] [Related]
7. HGF/NK4 inhibited VEGF-induced angiogenesis in in vitro cultured endothelial cells and in vivo rabbit model.
Nakabayashi M; Morishita R; Nakagami H; Kuba K; Matsumoto K; Nakamura T; Tano Y; Kaneda Y
Diabetologia; 2003 Jan; 46(1):115-23. PubMed ID: 12637990
[TBL] [Abstract][Full Text] [Related]
8. HGF-MET cascade, a key target for inhibiting cancer metastasis: the impact of NK4 discovery on cancer biology and therapeutics.
Mizuno S; Nakamura T
Int J Mol Sci; 2013 Jan; 14(1):888-919. PubMed ID: 23296269
[TBL] [Abstract][Full Text] [Related]
9. Structural and functional basis of the serine protease-like hepatocyte growth factor beta-chain in Met binding and signaling.
Kirchhofer D; Yao X; Peek M; Eigenbrot C; Lipari MT; Billeci KL; Maun HR; Moran P; Santell L; Wiesmann C; Lazarus RA
J Biol Chem; 2004 Sep; 279(38):39915-24. PubMed ID: 15218027
[TBL] [Abstract][Full Text] [Related]
10. NK4 gene therapy targeting HGF-Met and angiogenesis.
Matsumoto K; Nakamura T
Front Biosci; 2008 Jan; 13():1943-51. PubMed ID: 17981681
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of HGF/SF-induced breast cancer cell motility and invasion by the HGF/SF variant, NK4.
Hiscox S; Parr C; Nakamura T; Matsumoto K; Mansel RE; Jiang WG
Breast Cancer Res Treat; 2000 Feb; 59(3):245-54. PubMed ID: 10832594
[TBL] [Abstract][Full Text] [Related]
12. Noncompetitive inhibition of hepatocyte growth factor-dependent Met signaling by a phage-derived peptide.
Tam EM; Runyon ST; Santell L; Quan C; Yao X; Kirchhofer D; Skelton NJ; Lazarus RA
J Mol Biol; 2009 Jan; 385(1):79-90. PubMed ID: 18973760
[TBL] [Abstract][Full Text] [Related]
13. The HGF/SF antagonist NK4 reverses fibroblast- and HGF-induced prostate tumor growth and angiogenesis in vivo.
Davies G; Mason MD; Martin TA; Parr C; Watkins G; Lane J; Matsumoto K; Nakamura T; Jiang WG
Int J Cancer; 2003 Sep; 106(3):348-54. PubMed ID: 12845672
[TBL] [Abstract][Full Text] [Related]
14. Identification of functional domains in the hepatocyte growth factor and its receptor by molecular engineering.
Bardelli A; Ponzetto C; Comoglio PM
J Biotechnol; 1994 Sep; 37(2):109-22. PubMed ID: 7765452
[TBL] [Abstract][Full Text] [Related]
15. Radiation stimulates HGF receptor/c-Met expression that leads to amplifying cellular response to HGF stimulation via upregulated receptor tyrosine phosphorylation and MAP kinase activity in pancreatic cancer cells.
Qian LW; Mizumoto K; Inadome N; Nagai E; Sato N; Matsumoto K; Nakamura T; Tanaka M
Int J Cancer; 2003 May; 104(5):542-9. PubMed ID: 12594808
[TBL] [Abstract][Full Text] [Related]
16. Mast cell and neutrophil peptidases attack an inactivation segment in hepatocyte growth factor to generate NK4-like antagonists.
Raymond WW; Cruz AC; Caughey GH
J Biol Chem; 2006 Jan; 281(3):1489-94. PubMed ID: 16303761
[TBL] [Abstract][Full Text] [Related]
17. A functional domain in the heavy chain of scatter factor/hepatocyte growth factor binds the c-Met receptor and induces cell dissociation but not mitogenesis.
Hartmann G; Naldini L; Weidner KM; Sachs M; Vigna E; Comoglio PM; Birchmeier W
Proc Natl Acad Sci U S A; 1992 Dec; 89(23):11574-8. PubMed ID: 1280830
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of Met/HGF receptor and angiogenesis by NK4 leads to suppression of tumor growth and migration in malignant pleural mesothelioma.
Suzuki Y; Sakai K; Ueki J; Xu Q; Nakamura T; Shimada H; Nakamura T; Matsumoto K
Int J Cancer; 2010 Oct; 127(8):1948-57. PubMed ID: 20104519
[TBL] [Abstract][Full Text] [Related]
19. Dissociation of heparan sulfate and receptor binding domains of hepatocyte growth factor reveals that heparan sulfate-c-met interaction facilitates signaling.
Rubin JS; Day RM; Breckenridge D; Atabey N; Taylor WG; Stahl SJ; Wingfield PT; Kaufman JD; Schwall R; Bottaro DP
J Biol Chem; 2001 Aug; 276(35):32977-83. PubMed ID: 11435444
[TBL] [Abstract][Full Text] [Related]
20. Allosteric peptide activators of pro-hepatocyte growth factor stimulate Met signaling.
Landgraf KE; Santell L; Billeci KL; Quan C; Young JC; Maun HR; Kirchhofer D; Lazarus RA
J Biol Chem; 2010 Dec; 285(51):40362-72. PubMed ID: 20937841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
